Install
Please confirm you are human
This browser or connection looks automated. Press and continuously hold the control for 3 seconds to enable Google-hosted web results and, when separately allowed, AI-assisted answers.
A successful check enables 100 search requests. Interactive access does not authorize scraping, systematic collection, or reuse of search output.
News
Dayspring Pharma's CG2001 Meets Phase II Endpoint in Male Androgenetic Alopecia Trial
3+ mon, 5+ day ago (180+ words) 09 June 2026 | Tuesday | News CG2001 is a topical fixed-dose combination formulation containing minoxidil and finasteride, being evaluated for the treatment of male androgenetic alopecia. The trial consisted of the following treatment arms: CG2001 (5% Minoxidil and 0.075% Finasteride) once daily (QD); CG2001 (5% Minoxidil and 0.1% Finasteride) once…...
Alopecia Areata Pipeline Analysis: Next-Generation Immunotherapies and JAK Inhibitors Drive Innovation Across the Autoimmune Hair Loss Treatment Landscape | DelveInsight
3+ mon, 2+ week ago (71+ words) Alopecia Areata Pipeline Analysis: Next-Generation openPR.com Alopecia Areata Pipeline Analysis: Next-Generation Immunotherapies and JAK Inhibitors Drive Innovation Across the Autoimmune Hair Loss Treatment Landscape | DelveInsight Press release from: DelveIinsight Business Research Permanent link to this press release: You can…...
Expert Pearls on the Use of the FoLix Laser for Androgenetic Alopecia
4+ mon, 2+ day ago (113+ words) The Dermatology Digest Expert Pearls on the Use of the FoLix Laser for Androgenetic Alopecia With Dr. Jennifer Krejci Jennifer Krejci, MD, a Dermatologist at the Limmer Hair Transplant Center in San Antonio, TX, recently presented new data on FoLix…...
New Treatment Shows Promising Results in Hair Growth Trial
4+ mon, 2+ week ago (370+ words) More than 50 million men in the U.S. deal with hair loss, but the solutions haven’t kept their promise. Many treatments are inconvenient, inconsistent, or both. That’s why a new pill currently in phase 3 trials is getting attention: it aims to simplify…...
Veradermics’ Oral VDPHL01 Achieved Early, Consistent, and Robust Hair Growth in Positive Phase 2/3 ‘302’ Clinical Trial in Male Pattern Hair Loss
4+ mon, 2+ week ago (277+ words) VDPHL01, a novel orally-administered extended-release minoxidil formulation, met all primary and all key secondary endpoints with high statistical significance in both active treatment arms evaluating once-daily (QD) and twice-daily (BID) administration of VDPHL01 Rapid and robust hair growth was achieved with VDPHL01 treatment…...
Can Peptides Reverse Hair Loss?
4+ mon, 2+ week ago (209+ words) We tested OMI’s Hair Growth product to see—and shared our honest opinions. Before this, I’d only done hair growth treatments via ingestible, hydrolyzed collagen powder. I believe in the benefits—it makes my hair thicker, more… upholstered if you…...
Early, rapid growth seen with ’milestone’ hair loss pill: Topline data
4+ mon, 2+ week ago (223+ words) A proprietary extended-release oral minoxidil tablet yielded rapid and robust hair growth in men with pattern hair loss, according to topline results. Data from study 302, a phase 2/3 trial including more than 500 men with androgenic alopecia, suggest VDPHL01 (Veradermics) could potentially become…...
Veradermics to Hold Conference Call to Discuss Topline Results from Phase 2/3 ‘302’ Study of VDPHL01 in Males with Mild-to-Moderate Pattern Hair Loss
4+ mon, 2+ week ago (434+ words) BioSpace Veradermics to Hold Conference Call to Discuss Topline Results from Phase 2/3 ‘302’ Study of VDPHL01 in Males with Mild-to-Moderate Pattern Hair Loss Conference call will take place on Monday, April 27, 2026 at 8:00 am ET NEW HAVEN, Conn.--(BUSINESS WIRE)--Veradermics, Incorporated (NYSE:…...
Dayspring Pharma Reports Positive Phase II Results For CG2001 In Androgenetic Alopecia
4+ mon, 3+ week ago (210+ words) 23 April 2026 | Thursday | News Dayspring Pharma announced top-line data from its Phase II clinical trial of CG2001 foam in male patients with androgenetic alopecia (AGA). The trial met its primary endpoint and demonstrated statistically significant and clinically meaningful results, with a favorable…...
Nektar’s rezpeg more than worth its SALT in alopecia phase IIb
4+ mon, 3+ week ago (25+ words) BioWorld News Nektar’s rezpeg more than worth its SALT in alopecia phase IIb...